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Roquin binds microRNA-146a and Argonaute2
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Roquin is an RNA-binding protein that prevents autoimmunity and inﬂammation via
repression of bound target mRNAs such as inducible costimulator (Icos). When Roquin is
absent or mutated (Roquinsan), Icos is overexpressed in T cells. Here we show that Roquin
enhances Dicer-mediated processing of pre-miR-146a. Roquin also directly binds Argonaute2,
a central component of the RNA-induced silencing complex, and miR-146a, a microRNA that
targets Icos mRNA. In the absence of functional Roquin, miR-146a accumulates in T cells. Its
accumulation is not due to increased transcription or processing, rather due to enhanced
stability of mature miR-146a. This is associated with decreased 30 end uridylation of the
miRNA. Crystallographic studies reveal that Roquin contains a unique HEPN domain and
identify the structural basis of the ‘san’ mutation and Roquin’s ability to bind multiple RNAs.
Roquin emerges as a protein that can bind Ago2, miRNAs and target mRNAs, to control
homeostasis of both RNA species.
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P
osttranscriptional gene regulation by trans-acting RNA-
binding proteins is a rapid and efﬁcient way to modify gene
expression and cellular responses. Mutations in these trans-
acting factors are often associated with pathology1. The protein
Roquin (encoded by Rc3h1), known to bind target mRNAs and
promote their decay, has been found to be crucial in the
maintenance of peripheral immune tolerance. Mice either lacking
Roquin/Roquin2 or homozygous for the Roquin ‘san’ mutation
(sanroque mice) have impaired posttranscriptional regulation of
mRNAs in T cells and macrophages2–6. Roquin is a ubiquitously
expressed RING-E3 ubiquitin ligase family member containing a
highly conserved ROQ domain required for RNA binding and
localization to stress granules7,8 and a CCCH zinc ﬁnger motif.
Roquin binds a stem-loop structure termed the constitutive decay
element (CDE) within the 30-UTR of Tnf mRNA and recruits the
Ccr4-Caf1-Not deadenylation machinery leading to mRNA
decay6. mRNA degradation can also be mediated by Roquin’s
recruitment of Rck/Edc4/Dcp1a decapping complexes and is
thought to occur independently of miRNA activity8.
MicroRNAs (miRNAs) are small 20 22 nt non-coding RNAs
that regulate speciﬁc mRNA targets mainly by translational
inhibition and/or mRNA decay9. They are involved in most
cellular responses and their dysregulation has been shown to be
associated with autoimmune diseases10. Synthesized in the
nucleus as long primary transcripts, they are cleaved into
precursor miRNAs (pre-miRNAs) and exported to the
cytoplasm where the hairpin structure is processed by the
RNaseIII complex Dicer/Tarbp2 into the mature B22 nt long
imperfect miRNA duplex. This is loaded into the miRNA RNA-
induced silencing complex (miRISC), comprised of several
proteins including GW182 and Ago2. Once loaded into the
miRISC, miRNAs interact with sequences within target
mRNAs9,11.
Although much is known about miRNA biogenesis and
function, relatively little is known about miRNA homeostasis
and its importance in immunity or autoimmunity. Speciﬁc
nucleotides present in mature miRNAs, terminal-end modiﬁca-
tions of miRNAs like adenylation or uridylation and subcellular
localization have been shown to affect miRNA homeostasis but
none of these mechanisms has yet been shown to regulate miRNA
longevity in mammals12. Ribonucleases such as Sdn1 and Xrn1
regulate miRNA half-life in Arabidopsis and Caenorhabditis
elegans, respectively13 but evidence of a similar role in
mammalian cells is lacking. Recently Eri1, a highly conserved
30-to-50 exoribonuclease, was shown to regulate miRNA
homeostasis in murine lymphocytes but the exact mechanism is
still unknown14. Here we show that Roquin is one such regulator
of miRNA longevity. Roquin binds to miR-146a and its target Icos
mRNA and promotes their decay. Icos and miR-146a limit T
follicular helper (Tfh) cells to prevent the development of
autoantibodies and autoimmunity15. Roquin also forms a
complex with the RISC component Ago2. These data implicate
Roquin as a facilitator of miRNA-mediated target decay.
Results
Roquin represses miR-146a levels within T cells. We previously
reported that several miRNAs were upregulated in T cells
homozygous for the hypomorphic ‘san’ allele of Roquin3.
Genome-wide miRNA proﬁling of puriﬁed naive CD4þ T cells
(Fig. 1a) from Roquinsan/san and Roquinþ /þ control littermates
revealed 15 miRNAs were overexpressed by 4twofold in
Roquinsan/san T cells and none were downregulated (Fig. 1b and
Supplementary Table 1). miR-146a (mmu-miR-146a-5p) and
miR-21 (mmu-miR-21-5p) showed the greatest change: 25-fold
and 14-fold, respectively. Quantitative real-time PCR (qRT–PCR)
conﬁrmed the increase in miRNA expression levels (Fig. 1c),
which was not present in B cells, murine embryonic ﬁbroblasts
(MEFs) or other T-cell subsets (Supplementary Fig. 1a,b).
Quantiﬁcation of miR-146a in naive CD4þ T cells lacking both
Roquin and Roquin-2 also revealed miR-146a accumulation
(Fig. 1d) conﬁrming that the failure of Roquinsan to limit miR-
146a was a reﬂection of loss of function of the Roquin paralogues.
To test whether Roquinsan was acting within T cells to cause
the increase in miR-146a, we constructed mixed bone marrow
chimeric mice. For this, mice labelled with a congenic marker
(Ly5b) were sublethally irradiated and reconstituted with a 50:50
mix of Roquinsan/san.Ly5b and Roquinþ /þ .Ly5a bone marrow
cells. A control group was reconstituted with a 50:50 mix of
Roquinþ /þ .Ly5b and Roquinþ /þ . Ly5a bone marrow. Stem
cells present in the bone marrow can reconstitute the hemato-
poietic compartment of irradiated recipient mice and the
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Figure 1 | Loss of Roquin causes Tcell-autonomous miRNA accumulation.
(a) Flow cytometric stains from Roquinsan/san and Roquinþ /þ T cells
showing the gating strategy used to sort CD4þCD44loCD25 naive
T cells. (b) Scatter plot of microRNA expression in sorted naive T cells
obtained by microarray analysis. (c) qRT–PCR showing relative expression
levels of mature miR-146a and miR-21 in naive T cells, normalized to U6.
(d) Relative expression levels of miR-146a measured by qRT–PCR in
Rc3h1ﬂ/ﬂ;Rc3h2ﬂ/ﬂ; CD4-Cre double knockout naive T cells normalized
to snoRNA202. (e,f) qRT–PCR analysis of miR-146a (e) and miR-21
(f) in Roquinsan/san.Ly5b: Roquinþ /þ .Ly5a or of Roquinþ /þ .Ly5b:
Roquinþ /þ .Ly5a mixed chimeras. Each dot represents an individual mouse
and the bar represents the median value in each group. U-test: *Po0.02,
**Po0.05, ***Po0.005. See also Supplementary Fig. 1a,b.
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congenic markers Ly5a/b allow identiﬁcation of T cells from
Roquin mutant and wild-type origin. miR-146a was upregulated
in naive CD4þ T cells in a cell-autonomous fashion: only
Roquinsan/san (Ly5b) cells had elevated levels of this miRNA
compared with Roquinþ /þ (Ly5a) cells in the same mice
(Fig. 1e). In the case of miR-21, wild-type cells also had elevated
levels of this miRNA compared with the control chimeras
(Fig. 1f) suggesting a cell-extrinsic mechanism although a cell-
intrinsic component could not be excluded. These results show
that Roquin acts in T cells to repress miR-146a and possibly other
miRNAs.
Roquin enhances Dicer-mediated processing of pre-miR-146a.
To map the stage at which Roquin represses miR-146a accumu-
lation, we investigated the amount of primary and precursor
miRNAs present in naive T cells. qRT–PCR using three different
sets of primers to speciﬁcally amplify primary miR-146a in naive
T cells revealed no differences in the presence of Roquinsan
(Fig. 2a), and this observation extended to primers in the pre-
miR-146a region (Fig. 2b). Analysis of miR-146a by northern
blotting conﬁrmed the selective accumulation of mature
miR-146a in Roquinsan/san (Fig. 2c), and no accumulation of
control miR-150, a miRNA that did not change in Roquinsan/san
T cells. These results point to mature miR-146a accumulating
either during or after Dicer-mediated processing.
To investigate Roquin-mediated processing of precursor
miRNAs, we next quantiﬁed mature miR-146a in MEFs sufﬁcient
or deﬁcient in Dicer expression. MEFs were retrovirally
transduced with Roquinwt, Roquinsan or empty vector expressed
from an IRES-GFP reporter construct. Twenty-four hours after
transduction, all the cells were treated with tamoxifen that
removed Dicer from the CreER expressing cells only, and cells
were sorted for GFP expression after 1 week. miR-146a
accumulation was observed in Dicer-expressing MEFs transduced
with Roquinsan but accumulation did not occur in the absence of
Dicer (Fig. 2d). This indicates that Roquin-induced miR-146a
accumulation requires Dicer-mediated processing.
We next investigated whether Roquin itself has miRNA
processing activity in vitro and can cleave pre-miRNAs into their
mature form. Unlike Dicer, Roquin alone did not cleave pre-miR-
146a (Fig. 3a). Addition of Roquin enhanced Dicer’s cleavage
ability by B2.5-fold (Fig. 3b) suggesting that it may form a part
of the Dicer processing complex. Importantly, the ‘san’ mutation
in Roquin did not further enhance Dicer’s function (Fig. 3b)
suggesting that Roquin-induced enhancement of Dicer-mediated
processing is not the cause of mature miR-146a accumulation in
the presence of Roquinsan.
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Figure 2 | Post-transcriptional Dicer dependent accumulation of miR-146a. (a) Relative expression of pri-miR-146a in naive T cells sorted from
Roquinþ /þ and Roquinsan/san mice measured by qRT–PCR using three different sets of primers shown as (i), (ii) and (iii) in the schematic. NS, not
signiﬁcant (Po0.05, U-test). (b) The levels of pre-miR-146a in Roquinþ /þ and Roquinsan/san naive T cells measured by qRT–PCR. (c) Northern blots
showing precursor and mature miRNA transcripts (arrows) of miR-146a and miR-150 in naive T cells of Roquinsan/san and Roquinþ /þ mice. U6 snRNA
was used as a loading control and is shown below the miR-146a northern blot. Weaker less abundant bands are miRNA decay products. M, marker.
(d) Relative expression of miR-146a in Dicer-ﬂoxed-Rosa26-Cre-ER MEFs (Dicer1 / ) and CD4-CRE (wt) control MEFs assessed by qRT–PCR. MEFs were
retrovirally transduced with Roquinwt and Roquinsan containing a GFP reporter or with an empty GFP vector control. After 2 days, MEFs were treated
with tamoxifen to delete Dicer. GFP-positive cells were sorted 7 days later. Each dot represents individual mice (a,b) or technical replicates (d) and the bars
represent the median value in each group. U-test: *Po0.05, **Po0.005. Results are representative of two independent experiments.
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Roquin controls mature miRNA half-life. An explanation for
the accumulation of mature miR-146a is increased stability. miR-
146a decay was investigated after treatment with actinomycin D3
which prevents on-going transcription. The amount of miR-146a
dropped below 20% of initial levels within 0.5 h of actinomycin D
treatment in wild-type naive CD4þ T cells, whereas no decay was
observed in Roquinsan/san cells up to 3 h after treatment, pointing
to increased stability as the cause of miR-146a accumulation
(Fig. 4a). To study the effects of Roquin on miRNA half-life in
isolation from transcription-related events, we transfected
HEK293T cells (that express a negligible amount of miR-146a),
with synthetic precursor-like miR-146a and either wild-type or
mutant Roquin-expressing constructs. Five days post transfection,
miR-146a levels had decayed by 50% in the presence of Roquinwt,
but only by 10% with Roquinsan (Fig. 4b). A scramble control
miRNA had no effect (Supplementary Fig. 2a). In parallel
experiments, retroviruses expressing pre-miR-146a along with
retroviral Roquinwt IRES-GFP or Roquinsan IRES-GFP were used
to transduce wild-type MEFs. GFPþ cells were sorted 7 days later
and miR-146a was again found to be signiﬁcantly higher in
Roquinsan expressing cells (Fig. 4c). Together these results
demonstrate that Roquin acts to regulate miRNA decay.
Intracellular localization of miR-146a was investigated by
in situ hybridization. Cytoplasmic miR-146aþ granules were
readily visible in Roquinsan/san naive T cells but not clearly
appreciable in control T cells, which precluded comparative
quantiﬁcation. miR-146a did not co-localize with the P-body
marker Dcp-1, whereas some miR-146aþ granules were
eIF3þ (Supplementary Fig. 2b) suggesting localization to stress
granules. miRNAs are stored in exosomes particularly
when found in excess16. Consistent with this, there was
increased miR-146a within exosomes in Roquinsan/san T cells
in the presence of comparable total numbers of exosomes
(Supplementary Fig. 2c–e).
MiRNA editing and tailing17 has been shown to affect miRNA
stability in plants18 and mammals19,20. Decreased uridylation has
been speciﬁcally associated with increased miRNA stability and
abundance19–21. To investigate possible differences in non-
templated additions of miR-146a in the presence of mutant
Roquin, small RNA deep sequencing from Roquinþ /þ and
Roquinsan/san T cells was carried out. As expected, reads were
primarily 22 nt in length (Supplementary Fig. 3a), and differential
expression analysis (Supplementary Fig. 3b) conﬁrmed the trends
seen with the earlier microarray data (Fig. 1b). Activated
Roquinsan/san CD4þ T cells expressed higher levels of miR-
146a (Fig. 5a). Overall, non-templated addition was seen largely
restricted to A and U and there was no pronounced global change
between wild-type and mutant (Fig. 5b). Next, we ranked
miRNAs by change in mono-uridylation. Out of 364 analysed
miRNAs, miR-146a alongside 39 additional miRNAs were in the
top quartile of decreased uridylation (Supplementary Fig. 3c):
compared with Roquinþ /þ T cells, miRNA-146a uridylation
decreased by 4% in Roquinsan/san (Fig. 5c) T cells. In summary,
defective Roquin leads to an increase in miR-146 half-life
associated with decreased mono-uridylation and accumulation
of the miRNA in exosomes.
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Figure 3 | Roquin enhances Dicer mediated pre-miR-146a processing.
(a) In vitro processing of pre-miR-146a in HEK293T cells after transfection
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transfection with FLAG-Dicer (lane 2) alone, or co-transfection of
FLAG-Dicer with either Roquinwt-GFP (lane 3) or Roquinsan-GFP (lane 4).
Lane 1: No transfection control. The lower panels show densitometric
analysis of the northern blots to quantify 32P. The ratios of the mature
versus precursor miRNA intensities are plotted. Intermediates or low
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Roquin binds to miR-146a in vitro and in vivo. MiR-146a binds
two Icos target sites (TS1 and TS2) that ﬂank the CDE within Icos
30-UTR (Supplementary Fig. 6)15. Roquin7,8 and miR-146a also
repress Icos mRNA (Pratama et al., submitted). To test whether
Roquin can bind miR-146a, we immunoprecipitated Roquin from
mouse CD4þ T cell lysates and quantiﬁed the amount of miR-
146a in the precipitate by qRT–PCR. The pull-down using an
anti-Roquin polyclonal antibody contained approximately
fourfold more miR-146a compared with pull-downs using
isotype control or Roquin antibody pre-incubated with a
blocking Roquin peptide (Fig. 5d). U6 was ampliﬁed as a
control; no statistically signiﬁcant increase speciﬁc to Roquin
antibody was observed (Fig. 5d). These results show that Roquin
forms a complex with mature miR-146a.
To conﬁrm that this was a direct interaction, we used surface
plasmon resonance (SPR) experiments with the amino (N)-
terminal 1 484 fragment of Roquin (RoquinWT1–484) that
contains the ROQ and CCCH RNA-binding domains previously
shown to bind ICOS mRNA by SPR7. Both wild-type and mutant
Roquin (RoquinM199R1–484) were capable of binding miR-146a
(Fig. 5e,f) but not miR-21 (data not shown). Binding afﬁnity was
approximately threefold higher for mutant Roquin (Fig. 5e,f) as
previously observed for Icos mRNA7.
The structure of Roquin reveals novel RNA-binding domains.
To gain insight into the molecular details of the interaction of
Roquin with RNA, we determined the crystal structures of the
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370±50nM (WT). Fit Rmax values were 330±20 (for WT) and 242±13 response units (M199R).
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ROQ domain (residues 177–326, to 2.2 Å) and a larger construct
containing the RING, ROQ and zinc-ﬁnger domains (residues
1–484, to 2.75Å) that incorporated the ‘san’ mutation M199R
(Table 1). There were two copies of the ROQ domain in the
asymmetric unit of the ﬁrst structure, with a dimer interface of
759Å2. Although there was only one molecule in the asymmetric
unit of the larger Roquin construct, an identical dimer interface
was preserved in the crystal lattice. Although recombinant
Roquin protein appeared to be monomeric in solution (data not
shown), conservation of the dimer interface in two different
crystal forms suggests that it may be biologically relevant
(Supplementary Fig. 4a).
The structure of Roquin1–484 revealed novel and unexpected
domain architecture (Fig. 6a). The RING and ROQ domains
could be clearly discerned while there was no electron density
associated with the zinc-ﬁnger domain, suggesting it is connected
to the core of the protein by a ﬂexible linker. Surprisingly, regions
of the protein, both N- and carboxy (C)-terminal to the ROQ
domain combined to form a HEPN (higher eukaryotes and
prokaryotes nucleotide-binding) domain that was not predicted
on the basis of sequence. Between the ROQ and HEPN domains
is a large concave, positively charged surface reminiscent of
nucleic acid-binding sites (Fig. 6b). The HEPN domain consists of
a bundle of ﬁve a-helices (Fig. 6c, light blue) in an up-down-
down-up-down conﬁguration. HEPN domains are ubiquitous in
bacteria and have been incorporated into several higher
eukaryotic proteins such as human SACSIN (PDB ID 3O10).
This was identiﬁed as the closest structural homologue using
DALI, with root mean squared deviation (r.m.s.d.) of 2.4 Å
(Fig. 6c, grey). An additional helix is N-terminal to the HEPN
domain, providing extra contact between it and the RING
domain.
In Roquin, the 150-residue ROQ domain is inserted between
helices 2 and 3 of the HEPN domain (Fig. 6a, beige) and is mostly
a-helical. The domain boundaries differed slightly from those
suggested by earlier sequence analyses (Fig. 6a). It has seven a-
helices interrupted by a short b-strand between helices 2 and 3
and a b-hairpin between helices 4 and 5 (a1-a2-b1-a3-a4-a2-a3-
a5-a6-a7). There are no other examples of the overall fold of the
ROQ domain in the Protein Data Bank, and therefore this can be
considered a new protein fold. The closest structural homologue
is the RNA-binding domain of NusB (Fig. 6d, r.m.s.d. 3.3 Å over
88 residues). The ROQ domain can be subdivided into an
N-terminal winged helix–turn–helix (a2 to b3), followed by a
C-terminal helix–turn–helix (lacking the ‘wing’ of the ﬁrst, a5 to
a7). These were preceded by an extra helix (a1) that appears to
stabilize the relative orientation of the two sub-domains. The
winged helix–turn–helix (P197–E271) has B30% sequence
identity to DNA-binding Forkhead proteins, and clear structural
homology to DNA/RNA-binding proteins including CDT1
(r.m.s.d. 2.8 Å over 83 residues) and ADAR1 (2.6 Å over 62
residues; Fig. 6d).
The RING domain of Roquin adopts the typical zinc-
coordinated fold typical of many E3 ubiquitin ligase RING
domains. Two atoms of zinc could be clearly discerned in the
Roquin structure. One was coordinated by the side-chains of four
cysteine residues (C14, C17, C38, C41), while the other was
coordinated by two cysteines, a histidine and an aspartate (C33,
H35, C50, D53) (Fig. 6e). The presence of an aspartate in the
coordination sphere of the second zinc is unusual but not
unique22.
A comparison of our Roquin1–484 structure with that of the
wild-type ROQ domain demonstrated that the M199R mutation
induces only a minor conformational perturbation but one that is
likely to interfere with binding to either an RNA or a protein
ligand (Fig. 6f). Although M199 and R199 occupied a similar
spatial position, the presence of the mutation (located at the N
terminus of a2) resulted in distortion of the C terminus of nearby
a3 and the loop that follows it (Fig. 6f, Supplementary Fig. 4b). In
particular, E231 and R233 are shifted signiﬁcantly and F234 ﬂips
out from its position between a2 and a3 to become completely
solvent exposed. In fact, the conformational change caused by this
mutation allows for a crystal contact that is not present in the
wild-type protein. RoquinWT1–484 did not crystallize under this
or any other condition.
Roquin interacts with the core component of miRISC. Roquin
binds both miR-146a and its mRNA target (Icos), and it shares
structural homology with proteins that bind RISC proteins
(i.e., ADAR1 (ref. 23)) suggesting that Roquin may itself interact
with components of the miRISC complex. We ﬁrst looked at
whether Roquin interacted with Dicer but did not detect an inter-
action between these proteins when coexpressed in HEK293T
(Supplementary Fig. 5a). To investigate a possible interaction
between Roquin and the central miRISC component Ago2, V5-
Roquin and Ago2-Flag were transfected into 293T cells and the
tagged proteins immunoprecipitated. Western blots revealed a
weak unidirectional interaction between Roquin and Ago2. This
weak one-way interaction was also evident when we immuno-
precipitated endogenous Roquin with Ago2 from the murine cell
line EL4 (Supplementary Fig. 5b). The interaction was RNA
independent as it was also seen in the presence of RNase, which
Table 1 | Data collection and reﬁnement statistics.
RoquinM199R1–484
(Zn SAD)
RoquinWT133–344
Data collection
Space group C121 C2221
Cell dimensions
a, b, c (Å) 142.80, 80.19, 54.86 55.00, 78.32, 184.08
a, b, g () 90.00, 111.06, 90.00 90.00, 90.00, 90.00
Resolution (Å)w 2.75 (2.85–2.75) 2.20 (2.28–2.20)
Rmerge (%)w 11.08 (486) 9.7 (55.2)
I/s(I) 14.42 (0.52) 17.4 (2.8)
Completeness (%) 98.56 (97.93) 97.4 (90.3)
Redundancy 7.6 (7.7) 8.7 (6.9)
CC1/2w 0.999 (0.16) (0.862)
Reﬁnement
Resolution (Å)w 2.75 (2.90–2.75) 2.20 (2.28–2.20)
No. of unique
reﬂections
14,921 (1,463) 20,060 (2,040)
Rwork/Rfree 21.84/25.53
(41.07/40.02)
21.67/25.21
(22.59/30.00)
No. of atoms
Protein 2,836 2,332
Ligands
Water 0 21
Zinc 2 0
Average B-factors
Protein 50.4 39.90
Ligand 68.3 94.90
R.m.s. deviations
Bond lengths (Å) 0.004 0.0053
Bond angles () 0.87 0.928
Values in parentheses are for highest-resolution shell.
wCriteria for data cut-off from ref. 53.
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abolished RNA-mediated interaction of PABP1 with Ago2 (ref.
24; Fig. 7a). To conﬁrm that this interaction occurred in vivo
between endogenously expressed proteins, we used in situ
proximity ligation assay (PLA), which allows the detection of
transient or weak protein interactions. The interaction was pro-
bed using mouse anti-Ago2 and rabbit anti-Roquin. Close
proximity (o20 nm) allows ligation and ampliﬁcation of com-
plementary DNA oligonucleotides on secondary antibodies and
visualization of individual protein interactions as ﬂuorescent dots.
Antibody staining was optimized on endogenous expression of
Ago2, Roquin and RCK (Supplementary Fig. 5c) and on exo-
genous expression of GFP (data not shown). PLA detected
interaction between Ago2 and Roquin similar to that of Roquin
with its known protein partner RCK8 and signiﬁcantly above
background levels seen with GFP (Fig. 7b,c). These results
support that Ago2 is a bona ﬁde and close binding partner of
Roquin.
Roquin has been shown to bind CDEs within target mRNAs6.
We compared the consequences of mutating the CDE within the
Icos 30-UTR and/or the miR-146a target sites or both (Fig. 7d).
Mouse primary T cells were retrovirally transduced with the
different Icos 30-UTR mRNA luciferase vectors (Fig. 7e).
Mutations in the miR-146a target sites exerted comparable
repression defects as the CDE mutation, and there were no
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Figure 6 | Crystal structure of Roquin fragments. (a) Structural and schematic representations of Roquin1–484. (i) Overall architecture of Roquin1–484
(RING domain¼ red, ROQ domain¼ beige, HEPN¼ light blue, additional helix packing against the HEPN domain¼ dark blue. (ii) Top: Schematic of the
known domain boundaries of Roquin before this work, middle/bottom: domain boundaries revealed by the crystal structure. Note that the ROQ domain is
an insertion in the HEPN domain. The ZnF (CCCH) domain was present in the crystallized protein but is not visible in the crystal structure. (b) Electrostatic
surface diagram of Roquin 1–484 (180 degrees rotated left to right), highlighting positively charged surfaces likely to be involved in RNA binding.
The surface indicated in the right hand panel is in a very similar location to the surface used by ADAR1 to bind nucleic acids. The orientation in the left
hand panel is identical to that in a(i). (c) Structural alignment of Roquin HEPN domain with HEPN domain from human Sacsin, (PDB ID:3O10, grey).
(d) Structural alignment of Roquin ROQ domain (beige) with NusB (PDB ID: 2JR0, orange) and the winged helix-turn-helix from ADAR1 (PDB ID:
1QBJ, orange). (e) Structure of the Roquin RING domain and schematic showing the residues involved in coordinating the two zinc atoms. (f) Residue
F234 is ﬂipped out of the structure in the ROQ M199R mutant, becoming solvent exposed. left: wild-type (green); middle: M199R (beige); right: overlay.
See also Supplementary Fig. 4.
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represents a technical replicate. U-test: ***Po0.001; **Po0.01. This is a representative of three independent assays.
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additive effects among the different sets of mutations (Fig. 7e).
These results show that miR-146a is as effective as Roquin in
repressing Icos suggesting that they may act in the same pathway,
that is, Roquin acts together with miR-146a to exert some or all of
the suppression.
Discussion
Our work identiﬁes a role of the immune modulator Roquin in
regulating mammalian miRNA homeostasis by promoting
mature miR-146a degradation. T cells expressing Roquinsan or
lacking Roquin and Roquin-2 displayed comparable accumula-
tion of miR-146a indicating that miRNA dysregulation is due to
the loss of the function of both Roquin paralogues. Although 15
miRNAs were elevated at least twofold, miR-146a and miR-21
were the ones most affected. Of these, only miR-146a accumu-
lated in a clearly cell-autonomous manner, suggesting a selective
effect of Roquin in the control of miR-146a homeostasis. Some of
the other upregulated miRNAs included miR-29b, miR-155 and
miR-500, which like miR-146a have been linked either to human
or to mouse lupus25.
Accumulation of miR-146a in Roquinsan/san T cells was not
found to be a transcriptionally regulated event: neither the
primary nor precursor miR-146a levels were different between
Roquin mutant and wild-type T cells. Moreover, Roquin does not
have a Dicer-like activity that cleaves pre-miRNAs into mature
forms. Roquin did enhance miR-146a processing by Dicer but
this was not further enhanced with Roquinsan excluding this as a
possible cause of miR-146a accumulation in Roquin mutant T
cells. The presence of mutant Roquin did prolong the half-life of
miR-146a, pointing to posttranscriptional stabilization of miR-
146a as the cause of the accumulation.
At least two non-mutually exclusive mechanisms may explain
miR-146a accumulation in the presence of mutant Roquin:
(i) target-mediated microRNA decay (TMMD) and (ii) decreased
mono-uridylation. Target mRNAs are not innocently submissive;
they can actively regulate the lifespan of the miRNAs that target
them. In C. elegans, binding of miRNAs to their targets can
promote target-mediated microRNA protection26, whereas in ﬂy
and mammalian cells. the opposite phenomenon—TMMD has
been described27–29. Given that Roquin binds not only miRNA
and target mRNA, but also the RISC component Ago2, it is likely
that in the absence of Roquin, a large fraction of cellular miR-
146a and target mRNAs are not bound to RISC and are therefore
protected from decay by TMMD. Roquin can bind to miR-146a,
Ago2 and at least one of miR-146a’s targets, Icos mRNA. Roquin
may bring miRNAs and their targets into proximity to recruit or
help stabilize RISC. Other RNA-binding proteins have been
shown to exert the opposite effect, for example, HuR aids miRISC
dissociation from its target RNA30. Decreased miR-146a mono-
uridylation found in the absence of functional Roquin may also
contribute to its increased stability: a role for uridylation in
enhancing miRNA decay has been described in plants18 and
mammals19,20. Intriguingly, HEPN domains are reported in
nucleotidyl-transferases31. This activity is required for terminal
miRNA uridylation; it is therefore tempting to speculate that
Roquin may form part of a nucleotidyl–transferase complex to
promote uridylation of a subset of miRNAs including miR-146a.
Of 39 miRNAs that showed decreased uridylation, only 6
appeared to accumulate in the presence of mutant Roquin.
Thus, if decreased uridylation is linked to increased miR-146a
stability, this effect is likely to be selective for a small subset of
miRNAs, perhaps depending on simultaneous recognition of
particular miRNA:mRNA sequences and structures.
Our Roquin structure reveals that the N terminus is composed
of RING, HEPN, ROQ and CCCH domains. The structure of the
HEPN and ROQ domains suggests that they are highly likely to
both function as RNA-binding domains. There are dozens of
different classes of RNA-binding domains in eukaryotes32 Most
RNA-binding proteins contain multiple RNA-binding units to
allow for sequence- or structure-speciﬁc RNA recognition33. In
the case of Roquin, we observe at least three different potential
RNA-binding domains, the ROQ, HEPN and CCCH domains.
The presence of the HEPN domain was unexpected based on
sequence analysis as it is discontinuous in the primary sequence
as a result of insertion of the ROQ domain between two a-helices
that are usually separated in HEPN domains by a variable loop.
To allow for recognition of larger RNA sequences or multiple
RNAs, many RNA-binding proteins either dimerize or contain
ﬂexible linkers between the individual RNA-binding domains33.
Roquin appears to use both of these approaches: we see evidence
of dimerization as well as the presence of a ﬂexible linker between
the HEPN and CCCH domains. One feature common to many
RNA-binding domains is the presence of a basic region on their
surface that promotes their interaction with the negatively
charged nucleic acid backbone. There are two highly positively
charged surfaces on Roquin: one is located on the HEPN domain
and its interface with the ROQ domain, whereas the other is
entirely within the ROQ domain. The latter is the same as the
surface used by ADAR1 to bind nucleic acids. ADAR1 complexes
with precursor miRNAs and with Dicer through direct protein–
protein interaction to also enhance Dicer-mediated pre-miRNA
cleavage and facilitate loading of miRNA onto the RISC23.
Roquin also appears to enhance both Dicer activity and facilitate
RISC assembly. This may be related to the signiﬁcant structural
similarity between the N-terminal subdomain of the ROQ
domain and the RNA-binding domains of ADAR1: all of them
have winged helix–turn–helix structures.
Comparison of wild-type and M199R ROQ domains revealed
that the ‘san’ mutation causes a structural change in the protein
that exposes an otherwise buried hydrophobic residue (F234).
Three separate studies in which structures of the ROQ and HEPN
domains of Roquin have been solved were published while this
paper was under review34–36. The two structures presented by
Tan et al., are of Roquin bound to RNA CDE motifs from
hmgxb3 and TNF mRNAs. These CDEs occupy the two RNA
binding sites on the ROQ and HEPN domains we predicted on
the basis of electrostatic considerations (Fig. 6b) and the two
structures are highly similar to the apo structure presented here
(r.m.s.d. of 1.9 and 1.1 Å, respectively) indicating that the HEPN
and ROQ domains of Roquin undergo only minor structural
alterations upon RNA binding. No conclusions regarding the
RING domain can be drawn as it is absent in all other structural
studies. A comparison of our san mutant Roquin with that of
RNA-bound wild-type Roquin structures34–36 indicates that the
san mutation does not induce any structural perturbation in
either of the RNA binding sites (with the exception of a slight
shift in the position of Serine 238). Therefore the severe
phenotype seen in the sanroque mouse is unlikely to be due to
altered RNA binding by Roquin and may instead be due to a
failure, by Roquin, to interact with other (protein) components of
the mRNA-silencing machinery. This is the subject of future
experiments.
Accumulation of miR-146a was more pronounced in naive T
cells, known to express genes with longer 30-UTR than those in
proliferating T cells37. The components of the miRNA machinery
also become less abundant as T cells differentiate into effector
cells38. In Dicer / MEFs, Roquin regulates Icos mRNA
independently of miRNAs8. The same study also reported that
the level of Icos repression by Roquin increased with the length of
the Icos 30-UTR, indicating that multiple sites in the 30-UTR may
be necessary to induce full repression by Roquin. It is therefore
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likely that Roquin regulates Icos and other target mRNAs via
several mechanisms that include microRNA-mediated repression
in some cell types.
Transcriptome-wide studies have shown that Roquin controls
the degradation of numerous mRNAs with conserved CDE stem-
loop motifs6. Mutations in the CDE exerted exactly the same
inhibitory effect on Icos mRNA degradation by Roquin as the
mutations in miR-146a target sites, with no additive effect. Thus,
it is possible that the suppressive effect of CDE and miR-146a
operates through the same pathway. Roquin may bind Icos CDE
and bring miR-146a to its target sites to facilitate miR-146a
repression of Icos. Collaboration between AU-rich element-
binding microRNAs and AU-rich element-binding proteins is
emerging as a prominent mechanism of 30-UTR-mediated
regulation of gene expression in mammalian cells39,40. As to
the question of whether binding of Roquin to the CDE facilitates
binding of Roquin to miR-146a, a study published while this
paper was under review34 conﬁrms that HsRoquin-1 has two
binding sites within the ROQ domain. RNA-binding studies
showed that the ROQ domain can bind CDEs in one site and
dsRNA in the other and that this binding can occur
simultaneously and also independently. Combined, these results
and ours suggest that binding of Roquin to the CDE may not be
needed to facilitate binding of Roquin to miR-146a. Interestingly
both RNA-binding sites were shown to be necessary for mRNA
decay. Roquin, with its unique structure and different RNA-
binding domains may thus be important not only for regulating
miRNA homeostasis but also for miRNA function. Further
understanding of this Roquin-miR-146a axis may illuminate
pathogenesis of inﬂammatory and autoimmune diseases.
Methods
Mice and bone marrow chimeras. C57BL/6(B6) and Roquinsan/san (sanroque)
mice were housed in pathogen free conditions at the Australian Phenomics facility
at Australian National University (ANU). Seven-to-ten-week-old mice of both
genders were used throughout. Rc3h1ﬂ/ﬂ;Rc3h2ﬂ/ﬂ; CD4-Cre mice were housed in a
pathogen-free barrier facility at the Helmholtz Zentrum, Mu¨nchen. For bone
marrow chimera reconstitutions, 2 106 cells were injected intravenously into 10–
12-week-old sublethally irradiated (500 cGy, X-rad) C57BL/6 Ly5a recipients and
analysed 12 weeks after reconstitution. The ANU Animal Ethics and Experi-
mentation Committee approved all animal procedures.
Flow cytometry and microRNA microarray. Single-cell suspensions from spleen
and lymph nodes were surface stained for 30min at 4 C. Mouse CD4þ naive T
cells (CD4þB220CD44loCD25 ) were sorted using mouse anti-CD4 1:400
(BioLegend cat#100422 ), anti-CD44 1:200 (BioLegend cat#103006), CD25 1:200
(BioLegend cat#101910) and B220 1:100 (BioLegend cat#103208). For bone mar-
row chimeras, CD45.1 1:200 (BioLegend cat#110722 )and CD45.2 1:200 (BioLe-
gend cat no#109824) congenic markers were used. Total RNA from T cells from
four wt and four mutant mice was extracted using mirVana microRNA isolation kit
(Ambion) and miRNA microarrays were performed using Agilent mouse miRNA-
v1_95_May07 chips at the Ramaciotti Center for Genomics (UNSW) and analysed
using the Genespring software (Agilent Technologies, Inc.)
qRT–PCR and northern blot. Total RNA was extracted using TRIzol (Life
Technologies). Complementary DNA (cDNA) was prepared using miScript RT kit
(Qiagen). qRT–PCR for mature and precursor miR-146a, miR-21 and control U6
was performed using the miScript Primer/Precursor Assays (Qiagen) and ampliﬁed
on an ABI 7900 Prism light cycler in the Biomolecular Resource Facility, ANU. The
primer sequences used for detecting primary miR-146a are provided in
Supplementary Table 2. The relative expression was calculated using the 2 ddct
method41.
For measurements of miR-146a in Rc3h1ﬂ/ﬂ:/Rc3h2ﬂ/ﬂ;Cd4-cre; FACS-sorted
naive (CD4þCD62LþCD44 ) T cells from three Rc3h1ﬂ/ﬂ:/Rc3h2ﬂ/ﬂ (wt) and
Rc3h1ﬂ/ﬂ:/Rc3h2ﬂ/ﬂ;Cd4-cre mice and one Roquinsan/san mouse were used. miRNA-
speciﬁc cDNA was prepared using TaqMan MicroRNA Reverse Transcription kit
(Applied Biosystems). The expression of miR-146a was measured by qRT–PCR
using mmu-miR-146a, snoRNA202 Taqman microRNA Assay (Applied
Biosystems) on a Light cycler 480II with the Light cycler 480 SW 1.5 software
(Roche).
For northern blot hybridization, 10 mg of total RNA extracted from naive T cells
was fractionated on polyacrylamide TBE gel and electroblotted onto Amersham
Hybond-Nþ membrane (GE Healthcare), The miRCURY LNA probes for miR-
146a, miR-150 and U6 (Exiqon) were radiolabelled at 50 end with g-32P ATP and
hybridized to the membrane overnight. Radioactive signals were detected with a
Typhoon FLA9000 (GE Healthcare).
Transfections and retroviral transductions. HEK293T cells were transfected
with plasmid DNA in six-well plates using Lipofectamine 2000. Roquinwt,
Roquinsan or empty vector expressed from an IRES-GFP. Co-transfections of DNA
vectors (4mg per well) along with a synthetic control or precursor hsa-miR-146a
(50 pM, Ambion) was done using Lipofectamine 2000 (Invitrogen) as per the
manufacturer’s protocol. The reporter constructs used in transfections and the
retroviral transduction method is described previously2.
In vitro RNA cleavage assays. In vitro RNA cleavage was performed as essentially
as described42. In brief, synthetic pre-mir-146a oligonucleotides (Integrated DNA
Technology) were radiolabelled by 50 phosphorylation with polynucleotide kinase
(NEB) and g32P-ATP. Resulting radiolabelled RNAs were then mixed with anti-
Flag (or anti-Flag plus anti-GFP) agarose beads (Sigma) coated with lysates from
HEK293T cells transiently transfected with various tagged constructs. Resulting
cleavage products were resolved on a urea/acrylamide gel, then visualized and
quantiﬁed by phosphorimaging.
Co-immunoprecipitations. Cells were lysed in IP buffer (1% NP-40, 20mM
Tris.HCl (pH¼ 7.4), 150mM NaCl, 1 EDTA-free protease inhibitor cocktail
(Roche)) for 20min on ice. The clariﬁed cell lysates were precleared overnight with
magnetic Protein G Dynabeads (Invitrogen). The lysates were incubated with 2 mg
of antibodies for 1 h and then with Protein G Dynabeads for an additional 3 h at
4 C before being washed and resuspended in 20 ml of 3X sample buffer (360mM
Tris (pH¼ 6.8), 6% SDS, 30% b-mercaptoethanol, 30% glycerol, 0.15% bromo-
phenol blue). The samples were boiled at 70 C for 10mins before use in SDS–
polyacrylamide gel electrophoresis(SDS–PAGE). Antibodies used for ectopically
expressed constructs were mouse anti-V5 (clone SV5-Pk1, Serotec cat#MCA1360),
anti-Flag (clone M2, Sigma cat#F1804), and mouse anti-CD71 (clone MEM-75,
Sigma cat# SAB4700515-100UG). Anti-PABP (Abcam, cat#ab21060) was used for
assessing RNase activity. For endogenous IPs, mouse anti-Ago2 mAb (Wako
cat#014-22023), polyclonal rabbit anti-Roquin (Novus cat#NB100-656) or control
mouse anti-CD71 (clone MEM-75, Sigma cat# SAB4700515-100UG) were used..
In situ PLA. PLA was performed according to the manufacturer’s protocol
(Duolink kit, Olink Bioscience, Uppsala, Sweden). Brieﬂy, HEK293T cells were
grown on coverslips and ﬁxed at room temperature (RT) with 3.7% formaldehyde
for 20min. After three washes with phosphate-buffered saline (PBS), cells were
blocked and permeabilized for 60min in 5% BSA/0.3% Triton-X100 at RT and
incubated with primary antibodies at optimized dilutions (rabbit anti-ROQUIN
1:75 (Novus Biologicals); with either mouse anti-RCK 1:150 (Santa Cruz Bio-
technology Inc.); mouse anti-Ago2 1:200 (WAKO Pure Chemical Industries) or
mouse anti-GFP 1:100 (Roche)) overnight in a humid chamber at 4 C. Slides were
washed three times in PBS/0.05% Tween20 and incubated with mouse minus and
rabbit plus PLA probes for 1 h at 37 C. Ligation was carried out for 30min and
ampliﬁcation for 100min at 37 C. Slides were washed, dried at RT in the dark and
mounted in mounting media with DAPI (Olink) to stain nuclei. The images were
taken on a Leica SP5 confocal microscope with a pin hole of 95.5 mm and a HCxPL
APO lambda blue  631.4 oil objective and quantiﬁed using the free software
ImageJ (NIH, Maryland, USA).
RNA immunoprecipitation. For RIP a buffy coat containing lymphocytes was
obtained using Ficoll-Paque (GE Healthcare) gradient separation. Total lympho-
cytes (60 106) from tonsils were lysed thoroughly in 1ml of polysome lysis buffer
(100mM KCl, 5mM MgCl2, 10mM HEPES, 0.5% NP-40, 1mM DTT, 0.1U ml 1
RNAse out and 25ml ml 1 protease inhibitor). The total lysate was precleared with
50 ml Protein G Dynabeads (Life Technologies) for 1 h at 4 C and simultaneously,
antibody-bead complex was formed by incubating 15 ml protein G Dynabeads with
3 mg of anti-human Roquin (Bethyl Laboratories cat#A300–514A) antibody or
control IgG antibody (Santa Cruz cat# sc-2027) for 2 h at 4 C. A control was
included in which the lysate was incubated with Roquin antibody and a blocking
peptide. This blocking peptide is the one used for immunization of rabbits to
produce the polyclonal anti-Roquin IgG antibody (Bethyl Laboratories, cat #.
A300–514A). 10% of the precleared total lysate was saved for use as total input and
the rest of the lysate was used for immunoprecipitation. The precleared lysate was
combined with antibody–bead complex and incubated at 4 C for 4 h. After four
washes with polysome lysis buffer, the last wash was done with polysome lysis
buffer containing 1M urea for 5min at 4 C on a rotating mixer. The beads were
then resuspended in 100 ml of polysome lysis buffer containing 0.1% SDS and
incubated at 50 C for 30min. After incubation, an equal volume of phenol–
chloroform was added and RNA was extracted using mirVana miRNA isolation kit
(Ambion). RNA was also extracted from the total input. cDNA was prepared using
miScript RT kit (Qiagen) and used for qRT–PCR for miRNAs using miScript
primers and SYBR Green kit from Qiagen. The Ct values were recorded and
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normalized to the Ct values of the total input. The amount of bound miRNA was
plotted as percentage enrichment with respective antibody immunoprecipitation.
Luciferase assays in primary T cells. Wild-type or mutated mouse Icos 30-UTR
(miR-146a TS1/2; CDE or combined TS1/2þCDE mutation) DNA fragments
were generated with XhoI-NotI (GeneArt; sequence presented in Supplementary
Fig. 6) and cloned into retroviral dual-luciferase reporter vector miR-Sens (kind gift
from P. Mathijs Voorhoeve). These vectors were then transfected into Phoenix
cells, and retroviral supernatants were harvested 48 h post transfection. Primary T
cells were retrovirally transduced by spinoculation. The Dual-Glo Luciferase
Reporter kit (Promega Corporation) was used to measure luciferase as described
previously43.
Small RNA deep sequencing. T cells from spleen and lymph nodes were enriched
with an EasySep Mouse T Cell Enrichment Kit (Stemcell, cat# 19751) to 490%
purity. RNA was prepared using TRIzol (Life Technologies) and the concentration
and integrity of total RNA was veriﬁed with an Agilent 2100 Bioanalyser. Small
RNA library construction and deep sequencing was done by Illumina HiSeq
Technology (Beijing Genomics Institute at Shenzhen). All raw reads were ﬁrst
trimmed to remove the sequencing adaptor (50-TCGTATGCCGTCTTCTGCT
TGT-30) by using the Trimmomatic software44 (parameters: -threads 6 -phred64
input.fq output.t.fq ILLUMINACLIP:adaptor.fa:2:30:10 MINLEN:18) retaining
reads that were at least 18 nt long. Then reads were mapped to the mouse reference
sequence consisting of the genome sequence (GRCm38), 18s rRNA (gi|374088232)
and 28 s rRNA (gi|120444900) using Bowtie (v1.0.1) software45. Parameters for
mapping were chosen such that three mismatches were allowed in the 18 nt seed
region (-n 3 –l 18), the sum of the quality values at the mismatch positions could
not exceed 150 (-e 150) and all possible alignments fulﬁlling these requirements
were reported (-a). Other parameters that may inﬂuence the alignment output were
--nomaqround --maxbts 800 -y --chunkmbs 4096. Alignment ﬁles were processed
to retain alignments of a read with only minimum mismatches using a Perl
script (Supplementary Information 1).
Expression counts. All 18–26 nt long sequenced tags were assigned to a mature
miRNA if their 50 start position was within ± 3 nt of the 50 start position of the
mature miRNA (miRBase v21). We call these tags as miRNA mapped tags from
here on. Tag counts for mature miRNA were normalized to correct for the library
size as follows. If the total tags obtained for a sample is denoted as ‘N’, and the raw
tags count for a mature miRNA is denoted as ‘n’, then the normalized tag count for
the mature miRNA refers to (n 1,000,000)/N.
30 non-templated modiﬁcations/additions. All miRNA-mapped tags that are
(a) 1 nt longer than the annotated mature miRNA, and (b) identical to the genome
reference sequence except the last nucleotide were considered as tags showing the
evidence of 30 non-templated modiﬁcations/additions (Supplementary Fig. 7).
The percentage for A,C,G or T non-templated modiﬁcation/addition was
calculated with respect to the sum of mature and all non-templated tags. For
example, as indicated in the Supplementary Fig. 7, the percentage for the non-
templated T would be t 100/(mþ tþ cþ g).
Protein expression and puriﬁcation. Roquin1–484. GST-Roquin1–484 proteins
were expressed in BL21DE3 grown overnight at 18 C in 0.1mM zinc acetate and
1mM IPTG. Pelleted cells were sonicated in R-buffer (20mM Tris-HCl pH 7.5,
500mM NaCl, 0.1mM zinc acetate) with protease inhibitors, RNase A, DNase and
lysozyme (Roche). Clariﬁed supernatant was bound to Glutathione Sepharose resin
and the tag cleaved with PreScission Protease (GE Healthcare). Eluates were
fractionated on a Superdex 200 26/60 column (GE Healthcare). Fractions were
analysed by SDS–PAGE and proteins concentrated to 30mgml 1.
Roq domain. The DNA fragment encoding the roq domain (amino acid residues
122–344) was inserted into the expression plasmid pDEST17 by recombination.
The expression construct contains C-terminal His tag. The protein was
overproduced in Escherichia coli strain B834 (DE3). Single colonies were picked
and allowed to grow in media containing TB Overnight Express (Novagen) for 5–
6 h at 37 C followed by 20 h at 25 C. The cell pellet was collected and frozen at
80 C until use. For protein puriﬁcation, the cell pellet was resuspended in buffer A
(25mM Tris (pH 7.5), 500mM NaCl, 30mM imidazole) with 0.1% Tween 20,
protease inhibitors and DNase. The suspension was passed through a cell disruptor
at 30 k.p.s.i. and then centrifuged for 30min at 30,000g at 4 C. The soluble fraction
was transferred to an Akta¨ Express equipped with a Ni-nitrilo-triacetic acid column
connected in-line to a Hiload 16/60 Superdex 75 gel ﬁltration column (GE
Healthcare). The Ni-nitrilo-triacetic acid column was washed using buffer A, eluted
using buffer B (25mM Tris (pH 7.5), 250mM NaCl, 250mM imidazole) before
transfer to the gel ﬁltration column equilibrated in buffer C (20mM Tris (pH 7.5),
200mM NaCl). Peak fraction collection was performed using the Akta¨ Express
software.
Surface plasmon resonance (SPR). RoquinWT1–484 and RoquinM199R1–484
were freshly dialyzed into SPR buffer (10mM Tris-HCl pH 7.4, 150mM NaCl,
1mM TCEP, 0.05% surfactant P-20). Measurements were made at 20 C on a
Biacore T100 SPR instrument (GE Healthcare) at a ﬂow rate of 50 ml min 1.
50-Biotinylated mmu-miR-146a (50-CUGAGAACUGAAUUCCAUGGGUUAUA
UCAAUGUCA-30) was purchased from Shanghai Gene Pharma Co. Biotinylated.
The RNA was dissolved in SPR buffer, heated to 80 C for 5min and cooled slowly
to allow secondary structure formation. It was immobilized at 20 nM onto a single
ﬂow cell of a streptavidin-coated Biacore (SA) chip (GE Healthcare) by injection at
10 ml min 1 for B100 s to get 200 response units. Details of association/dis-
sociation measurements are described in Supplementary Methods. A second ﬂow
cell was left underivatized for blank subtraction. Chip surfaces were regenerated by
injection of 1M MgCl2 for 1min at 5 ml min 1, leaving the RNA intact while
removing bound protein. Association was measured for 180 s and Roquin was
allowed to dissociate for 300 s before regeneration of the chip surfaces by injection
of 1M MgCl2 for 1min at 5 ml min 1, leaving the RNA intact while removing
bound protein. RoquinWT1–484 was used in twofold serial dilutions from 2,000–
7.8 nM, whereas RoquinM199R1–484 was from 1,000–3.9 nM, with injections for
each protein done in random order. Although experiments were repeated twice,
progressive degradation of the immobilized RNA prevented use of replicates in
data ﬁtting. A data set comprising the ﬁrst 10 cycles measured for each protein was
selected to minimize effects from chip degradation.
Crystallization and structure determination. Roq domain (Roquin 133–344).
Crystals of the Roq domain were grown by sitting drops at 20 C by mixing
10mgml 1 of the protein (20mM Tris-HCl pH7.5, 200mM NaCl) with the
condition including lithium chloride 0.2M and polyethylene 20% Glycol 3350.
Crystals were cryo-protected with mother liquor plus 22% glycerol including 0.5M
Kl for 20 s before vitriﬁcation in liquid nitrogen. MAD data were collected at 100 K
on beamline BM14 at ESRF (Grenoble, France) at wavelengths of 1.55000 (peak)
and 0.95350Å (remote). The diffraction data were processed and scaled with
HKL2000 program package46. Twenty-one iodine sites in an asymmetric unit were
assigned using SHELXD47 and used for the SAD phase calculation with SOLVE48,
resulting in the initial mean ﬁgure-of merit of 0.27 for all reﬂections. We improved
the phases using the program DM49. Further structure reﬁnement was carried out
by PHENIX50 using the remote data and manual model building with coot51. The
ﬁnal model showed an Rfree factor of 21.4% and an R factor of 25.9%. Detailed
statistics are summarized in Table 1. Ramachandran Statistics: 97.3% favoured,
2.7% allowed, zero outliers.
RoquinM199R1–484. Immediately before crystallization, protein was diluted to
10mgml 1 using 20mM Tris-HCl pH 7.5, 0.1mM zinc acetate, to reduce the
concentration of NaCl to 167mM. Crystallization was accomplished by hanging-
drop vapour-diffusion at 20 C using 2 ml drops, and a drop-ratio of 1:1
protein:precipitant. Precipitant was 0.1M CHES pH 9.5, 7–12% PEG 8000. Crystals
grew from phase separation as B100 mm rhombohedra. Crystals were cryo-
protected with mother liquor plus 25% ethylene glycol before vitriﬁcation in liquid
nitrogen. Zinc-SAD data were collected at 100K at the Australian Synchrotron on
beamline MX2, at a wavelength of 1.265102 Å. Data were integrated using XDS52
and scaled using XSCALE. Anomalous signal was present to B5Å (6.54–5.35Å:
Anomalous correlation 0.41, SigAno 1.3). Initially a data cut-off of 3.1 Å was used.
A molecular replacement solution was found using PHASER, using the ROQ
domain (above) as a model. Phases were improved using the anomalous signal
from zinc. Two Zn sites were found, and phases were calculated with a mean ﬁgure
of merit of 0.45 for all reﬂections. Structure reﬁnement was carried out in
PHENIX50 using and manual model building with coot51. After several rounds of
reﬁnement, data were re-processed to include data to 2.75 Å based on a CC1/2
40.1, as suggested by Karplus and Deiderichs53, with a signiﬁcant improvement in
map quality. Ramachandran statistics: 98.33% favoured, 1.67% allowed, zero
outliers.
Quantiﬁcation of secreted exosomes. Splenocytes were stained with B220-FITC,
CD3e-PE and 7AAD. B220-FITC CD3-PEhi/7-AADlo T cells were sorted. The
cells were incubated in anti-CD3e (BD Pharmingen) pre-coated six-well plates
(5 mgml 1) in exosome-depleted complete RPMI medium at 1 106 cellsml 1
with 2 mgml 1 anti-CD28 antibody (BD Pharmingen) and 20Uml 1 of rIL-2 at
37 C with 5% CO2 for 48 h. After centrifugation for 5min at 210 g, the supernatant
was ﬁltered through a 0.22-mm ﬁlter (Merck Millipore) and exosomes harvested by
ultracentrifugation at 100,000g for 1 h at 4 C. The exosome pellet was split into
two. Half was resuspended in PBS, stained with anti-mouse-CD9-PE antibody
(BioLegend) and run on a ﬂow cytometer along the controls (PBS only, PBS plus
anti-CD9-PE and unlabelled exosomes). RNA was extracted from the other half of
the exosome pellet using TRIzol (Life Technologies). All-in-one miRNA qRT–PCR
detection kit (GeneCopoeia) and validated primers for mature miRNAs (Gene-
Copoeia) were used to quantify mmu-miR-146a-5p and mmu-miR-150-5p.
Ampliﬁcation was detected on a 7900 HT Fast Real-Time PCR system (Applied
Biosystems) and relative amounts were calculated using the 2 dct.
In situ hybridization. Naive T cells were sorted from Roquinsan/san and
Roquinþ /þ mice. The cells were ﬁxed in 3.7% formaldehyde for 20min at RT.
Once ﬁxed, cells were washed once with dH2O (13,000 r.p.m. for 10min) and
spotted at 10,000 cells per 25 ml on superfrost plus slides (Thermo Scientiﬁc). The
slides were incubated at 37 C. Once the slides were completely dry, they were
washed once with 100% ethanol and treated with proteinase K (500 ngml 1) for
5min at RT. The slides were incubated with the prehybridization solution (Enzo
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Life Sciences, cat#33808) at 55 C for 15min. The cells were hybridized with 2 pM
RNA probe at 55 C in a moist chamber overnight. Alexa-488 conjugated miR-
146a LNA probe and Alexa-488 conjugated scrambled LNA probe were purchased
from Exiqon. After probe hybridization, cells were blocked with blocking buffer
(0.2 SSCþ 2% BSA) for 10min at RT. Primary antibody, Dcp1A (gift from J.
Lykke-Andersen, University of California San Diego), and eIf3 were added at a
dilution of 1/250 and incubated at RT for 2 h at 4 C. After three washes with PBST
(PBSþ 0.01% Tween), the slides were incubated with a secondary antibody, don-
key-anti-goat-Alexa 568 (Molecular Probes, Invitrogen, cat#A-11057) at RT for 2 h.
The cells were washed three times, 10min each with PBST. Before a ﬁnal wash with
PBST, cells were incubated with DAPI for 2min. Cells were mounted in Vecta-
shield (Vector Laboratories) and Images were taken using an Olympus IX71
microscope with DP controller software (Olympus) and compiled using Adobe
Photoshop software.
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